Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment.

ABSTRACT:

Objectives

In our previous 24-month study, we observed that teriparatide had some advantages over denosumab for bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIO) patients with prior bisphosphonate treatment. We conducted this extension study to investigate whether the advantage of teriparatide obtained in the first 2 years would be maintained after the switch to denosumab.

Materials and methods

We switched patients who had completed 24-month daily teriparatide treatment to denosumab (switch group, n=18) and compared their BMD every 6 months up to 48 months with the group who continued to receive denosumab (denosumab group, n=16).

Results

At 48 months, the lumbar spine BMD was significantly increased from baseline in both groups (denosumab: 10.4 ±

SUBMITTER: Hirooka Y 

PROVIDER: S-EPMC8503555 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature